Purpose
Chronic plaque psoriasis is associated with the presence of non-alcoholic fatty liver disease (NAFLD), but the magnitude of this association remains currently uncertain. We aimed to ...investigate the magnitude of the association between psoriasis and the risk of prevalent and incident NAFLD, and to assess whether psoriasis severity and/or psoriatic arthritis are associated with a greater risk of NAFLD.
Methods
A systematic review and meta-analysis of observational studies evaluating the association between psoriasis and NAFLD, as diagnosed by imaging or International Classification of Diseases codes was performed. Literature search on PubMed, Scopus and Web of Science on May 3, 2021 was undertaken. Studies using liver biopsy were not available. For the meta-analysis, the random-effects modelling was adopted.
Results
We identified 15 observational (case–control and cross-sectional) studies for a total of 249,933 patients with psoriasis (49% with NAFLD) and 1,491,402 controls (36% with NAFLD). Psoriasis was associated with prevalent NAFLD (
n
= 11 studies; pooled random-effects odds ratio OR 1.96, 95% CI 1.70–2.26;
I
2
= 97%,
p
< 0.01). Psoriatic patients with NAFLD had a higher mean psoriasis area and severity index (PASI) than their counterparts without NAFLD (
n
= 8 studies, pooled weighted mean difference: 3.93, 95% CI 2.01–5.84
; I
2
= 88%,
p
< 0.01). The risk of NAFLD was marginally higher in patients with psoriatic arthritis than in those with psoriasis alone (
n
= 5 studies, pooled random-effects OR 1.83, 95% CI 0.98–3.43;
I
2
= 64%,
p
= 0.03). Sensitivity analyses did not alter these findings. Funnel plot did not show any significant publication bias. A major limitation of the study was the high degree of heterogeneity across studies.
Conclusion
Psoriasis is associated with prevalent NAFLD and this risk parallels the severity of psoriasis.
Monkeypox virus infection: what dermatologist needs to know? Bellinato, F.; Gisondi, P.; Girolomoni, G.
Journal of the European Academy of Dermatology and Venereology,
August 2022, 2022-08-00, 20220801, Letnik:
36, Številka:
8
Journal Article
A systematic review of treatments for pityriasis lichenoides Bellinato, F.; Maurelli, M.; Gisondi, P. ...
Journal of the European Academy of Dermatology and Venereology,
November 2019, 2019-Nov, 2019-11-00, 20191101, Letnik:
33, Številka:
11
Journal Article
Recenzirano
Pityriasis lichenoides (PL) represents a spectrum of inflammatory skin diseases comprising pityriasis lichenoides et varioliformis acuta (PLEVA) and pityriasis lichenoides chronica (PLC). This study ...aimed to provide a summary of effective treatments for PL. A systematic review was performed according to PRISMA guidelines for studies investigating PL treatment including ≥3 subjects and published in English between 1 January 1970 and 15 April 2019. A total of 441 papers were screened, and 37 original manuscripts meeting the inclusion and exclusion criteria were found, including 12 case series, 18 reviews, four prospective studies, two comparative studies and a single randomized controlled study. In most studies, ultraviolet (UV) phototherapy (narrow‐band UVB, broadband UVB, UVA1 or PUVA) was used. Clearance rates with the different modalities are hardly comparable between different studies, ranging approximately between 70% and 100%. Narrow‐band UVB showed an efficacy similar to PUVA as such as the combination of UVA and UVB vs. PUVA. Oral erythromycin showed clearance rates ranging between 66% and 83%, whereas methotrexate up to 100% but in small and dated studies. Evidence for other treatments is scarce. There is a lack of high level of evidence studies on PL treatment. The interpretation of the results is biased by the possible auto‐resolution of the disease, the sample heterogeneity between children and adults and the short follow‐up period of the studies. Only some studies investigated how results were durable after cessation of therapy. Quality of life and the impact of treatment were never assessed. According to the results of this review, we suggest narrow‐band UVB phototherapy as first‐line treatment. Oral erythromycin with or without topical corticosteroids and low‐dose methotrexate as second‐line therapies. High‐powered studies and randomized controlled trials are needed to establish the optimal treatment for PL.
Summary
Background
Acquired perforating dermatoses (APDs) are characterized by transepidermal elimination of skin materials. Altered glycation of dermal components may be involved in pathogenesis.
...Aim
To assess whether patients affected by APDs have increased levels of cutaneous advanced glycation end‐products (AGEs).
Methods
A cross‐sectional controlled study involving a total of 109 patients was conducted, enrolling 29 patients consecutively diagnosed with primary APDs reactive perforating collagenosis (RPC), elastosis perforans serpiginosa (EPS), perforating folliculitis (PF) and Kyrle disease (KD), 40 age‐ and sex‐matched healthy controls (HCs) and 40 patients with mild atopic dermatitis (AD). The levels of cutaneous AGEs were measured using a validated fluorescence technique.
Results
The median skin autofluorescence value in patients with APDs was significantly higher 2.7 arbitrary units (AU), interquartile range (IQR) 1.9–3.9 AU compared with HCs (1.8 AU, IQR 1.6–2.3 AU; P < 0.001) and patients with AD (2.1 AU, IQR 1.9–2.3 AU; P = 0.01). Median values were 3.5 AU (IQR 2.7–4.6 AU) for RPC, 1.83.5 AU (1.4–2.4 AU) for EPS, 3.1 AU (2.4–4.4 AU) for PF and 2.6 AU (2.3–3.1 AU) for KD.
Conclusions
Our results may suggest a possible physiopathological role of AGEs in the transepidermal elimination mechanisms involved in certain APDs.
Acquired perforating dermatoses (APDs) are characterized by transepidermal elimination of skin materials. Patients with APDs show higher cutaneous advanced glycation end‐products levels compared to the expected value for healthy patients and to patients with mild atopic eczema. Altered glycation of skin materials may be involved in the pathogenesis of certain APDs.
Impact of the COVID‐19 pandemic on melanoma diagnosis Gisondi, P.; Cazzaniga, S.; Di Leo, S. ...
Journal of the European Academy of Dermatology and Venereology,
November 2021, Letnik:
35, Številka:
11
Journal Article
PDF
